Friday, January 15, 2021 Daily Archives

Thermo Fisher adds EU viral vector plants in €725m Novasep deal

by

Thermo Fisher adds three Belgian facilities to its gene therapy contract manufacturing business. The sale is the latest divestment by Novasep. Thermo Fisher paid approximately €725 million ($878 million) to acquire Novasep’s Henogen viral vector manufacturing business, a business that brought in around €80 million in revenues in 2020. The deal bolsters Thermo Fisher’s gene therapy capabilities, adding 7,000 square meters of manufacturing space tand 400 staff through three facilities at two locations in Seneffe and Gosselies, Belgium. Thermo Fisher…

January 15, 2021

Adverum: ‘Scarcity of AAV capacity drove inhouse investment’

by

Adverum has invested $80 million into a North Carolina viral vector facility to support gene therapy candidate ADVM-022.  The GMP adeno-associated virus (AAV) manufacturing facility will be in Durham, North Carolina. Once operational in 2023, the 174,000 square-foot facility will boast 4,000 L of bioreactor capacity and create 200 jobs. The inhouse facility will support large-scale production of Adverum’s ADVM-022, which is a potential gene therapy using “a single intravitreal injection targeting two mass markets – wet AMD and diabetic…

January 15, 2021

Double Dutch: Cristal and Intravacc team on vaccine tech

by

The partnership looks to develop vaccines using Intravacc’s outer membrane vesicles (OMV) tech and Cristal Therapeutic’s copper-free click chemistry reagent with an initial target being COVID-19. The two companies will work together to develop novel vaccine programs with initial work during the evaluation period taking place at Cristal’s facility, followed by the further work conducted at Intravacc’s facility, both in the Netherlands. Financial details of the collaboration have not been divulged. Initially, the partnership is targeting a vaccine against COVID-19.…

January 15, 2021